Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm ; 655: 123996, 2024 Apr 25.
Article in English | MEDLINE | ID: mdl-38490404

ABSTRACT

The immunomodulatory properties of ß-glucans have sparked interest among various medical fields. As vaccine adjuvants, glucan particles offer additional advantages as antigen delivery systems. This study reported the immunomodulatory properties of glucan particles with different size and chemical composition. The effect of glucan microparticles (GPs) and glucan nanoparticles (Glu 130 and 355 NPs) was evaluated on human immune cells. While GPs and Glu 355 NPs demonstrated substantial interaction with Dectin-1 receptor on monocytes, Glu 130 NPs exhibited reduced activation of this receptor. This observation was substantiated by blocking Dectin-1, resulting in inhibition of reactive oxygen species production induced by GPs and Glu 355 NPs. Notably, monocyte-derived dendritic cells (moDCs) stimulated by Glu 355 NPs exhibited phenotypic and functional maturation, essential for antigen cross-presentation. The immunomodulatory efficacy was investigated using an autologous mixed lymphocyte reaction (AMLR), resulting in considerable rates of lymphocyte proliferation and an intriguing profile of cytokine and chemokine release. Our findings highlight the importance of meticulously characterizing the size and chemical composition of ß-glucan particles to draw accurate conclusions regarding their immunomodulatory activity. This in vitro model mimics the human cellular immune response, and the results obtained endorse the use of ß-glucan-based delivery systems as future vaccine adjuvants.


Subject(s)
Glucans , beta-Glucans , Humans , Glucans/pharmacology , Adjuvants, Immunologic/pharmacology , Adjuvants, Immunologic/chemistry , Adjuvants, Vaccine , beta-Glucans/pharmacology , beta-Glucans/chemistry , Antigens
2.
Methods Mol Biol ; 2412: 269-280, 2022.
Article in English | MEDLINE | ID: mdl-34918250

ABSTRACT

Beta-glucans are a group of polysaccharides with intrinsic immunostimulatory properties which makes the design of new particulate vaccine adjuvants based on ß-glucans very promising. The size of the particles and the antigen loading method, encapsulated into particles or adsorbed on its surface, will influence the toxicological and adjuvanticity properties of the particulate adjuvant. Herein we describe the production of glucan nanoparticles (NPs) with three different sizes, approximately 150 nm, 350 nm, and microparticles as shells (GPs) with approximately 3 µm. The association of the antigen to the particulate adjuvant is described using model protein antigens. The method can be easily adapted for real protein antigens.


Subject(s)
Nanoparticles , Adjuvants, Immunologic , Adjuvants, Pharmaceutic , Adjuvants, Vaccine , Antigens , Glucans , beta-Glucans
3.
Chem Res Toxicol ; 33(11): 2819-2833, 2020 11 16.
Article in English | MEDLINE | ID: mdl-33050694

ABSTRACT

Poly-ε-caprolactone (PCL) is a biodegradable polyester that has FDA and CE approval as a medical device. Nonetheless, the lack of toxicity exhibited by the polymer cannot be extrapolated to its nanomaterial conformation. Despite PCL-based NPs being widely studied in the biomedical field for their advantages as controlled drug delivery systems, little data describe PCL NPs' toxicity, particularly immunotoxicity. This work assessed different PCL-based delivery systems intended for protein delivery regarding their immunotoxicity and hemocompatibility. Two different molecular weight PCL polymers were used, as well as blends with chitosan and glucan. Results showed that the presence of NaOH during the production of PCL2 NPs and PCL2/glucan NPs induced PCL alkali hydrolysis, generating more reactive groups (carboxyl and hydroxyl) that contributed to an increased toxicity of the NPs (higher reduction in peripheral blood mononuclear cell viability and lower hemocompatibility). PCL2/glucan NPs showed an anti-inflammatory activity characterized by the inhibition of LPS stimulated nitric oxide (NO) and TNF-α. In conclusion, generalizations among different PCL NP delivery systems must be avoided, and immunotoxicity assessments should be performed in the early stage of product development to increase the clinical success of the nanomedicine.


Subject(s)
Nanoparticles/chemistry , Polyesters/chemistry , Animals , Cell Line , Cell Survival/drug effects , Cytokines/biosynthesis , Humans , Hydrolysis , Mice , Molecular Weight , Nitric Oxide/biosynthesis , Particle Size , Polyesters/pharmacology , RAW 264.7 Cells , Reactive Oxygen Species/metabolism
4.
AAPS PharmSciTech ; 20(3): 132, 2019 Feb 28.
Article in English | MEDLINE | ID: mdl-30820699

ABSTRACT

Among non-viral vectors, the cationic polymer chitosan has gained attention as a gene delivery system. We hypothesized that the addition of casein into the nanoparticle's structure would facilitate a proper gene transfer. The work herein presented aimed to optimize the production method of chitosan-casein nanoparticles (ChiCas NPs) and to test their ability as a gene delivery system. ChiCas NPs formulation optimization was carried out by analyzing several characteristics such as NP size, zeta potential, and chitosan and casein incorporation efficacy. The best formulation developed presented small and homogenous particle size (around 335 nm) and positive zeta potential (≈ + 38 mV), and showed to be stable for 34 weeks both, at 4°C and 20°C. The particles were further used to entrap or to adsorb DNA and form NPs-DNA complexes. In vitro transfection studies, carried out in COS-7 cells, suggested a low transfection efficiency of the different NPs:DNA ratios tested, comparatively to the positive control. Nonetheless, we could observe that the complexes with larger sizes presented better transfection results than those with smaller diameters. To conclude, ChiCas NPs have great technological potential since the preparation process is very simple, and the DNA incorporation efficacy is very high and shows to be physically very stable. The NPs:DNA ratio still needs to be optimized with the aim of achieving better transfection results and being able to anticipate a high gene expression on DNA-based vaccination studies.


Subject(s)
Caseins/chemistry , Chitosan/chemistry , Gene Transfer Techniques , Nanoparticles/chemistry , Particle Size , Transfection/methods , Animals , COS Cells , Caseins/administration & dosage , Caseins/pharmacokinetics , Chitosan/administration & dosage , Chitosan/pharmacokinetics , Chlorocebus aethiops , DNA/administration & dosage , DNA/chemistry , DNA/pharmacokinetics , Drug Stability , Genetic Therapy/methods , Nanoparticles/administration & dosage , Nanoparticles/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...